1. Home
  2. CME
  3. Ophthalmology
advertisement

The European Approach to Preservative-Free Pharmaceuticals: A Conversation With Dr. Anton Hommer

0.25 credits

CME/CE Broadcast Replay

The European Approach to PreservativeFree Pharmaceuticals A Conversation With Dr Anton Hommer
Restart
Resume
Choose a format
Take Post-Test
0.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters

  • Overview

    In this video, Anton Hommer, MD, discusses the European perspective on adopting preservative-free pharmaceuticals, highlighting challenges like health care professionals’ reluctancy to change, diverse reimbursement systems, and higher costs. He compares single-use and multiuse drugs, considering factors such as environmental impact and cost-effectiveness. Dr. Hommer emphasizes the superior efficacy of preservative-free medications, especially in treating chronic conditions such as glaucoma, and anticipates an increase in their use to protect ocular health and enhance chronic disease management.

    This activity is supported by an independent medical education grant from Théa Pharma.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Review the perceptions of preservatives on a global scale and discuss changes observed in patients after implementing preservative-free therapies

  • Accreditation

    Jointly Provided by Evolve Medical Education and The Fundingsland Group.

              

    Accreditation Statement
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC (Evolve) and The Fundingsland Group. Evolve is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation Statement
    Evolve Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Participation Method

    In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

  • Faculty and Disclosures

    Anton Hommer, MD

    Anton Hommer, MD

    Private office for Ophthalmology
    and Optometry
    Vienna, Austria

     

    DISCLOSURE POLICY
    It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

    The following faculty/staff members have the following financial relationships with ineligible companies.

    Anton Hommer, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Nidek. Speaker's Bureau: AbbVie, Interzeag, Santen, and Théa Pharma.

    The Evolve and The Fundingsland Group staff and planners have no financial relationships with ineligible companies.
    Nisha Mukherjee, MD, peer reviewer, has no financial relationships with ineligible companies.

  • Disclaimer

    OFF-LABEL STATEMENT
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group, or Théa Pharma.

    This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Recommended
Details
Presenters

  • Overview

    In this video, Anton Hommer, MD, discusses the European perspective on adopting preservative-free pharmaceuticals, highlighting challenges like health care professionals’ reluctancy to change, diverse reimbursement systems, and higher costs. He compares single-use and multiuse drugs, considering factors such as environmental impact and cost-effectiveness. Dr. Hommer emphasizes the superior efficacy of preservative-free medications, especially in treating chronic conditions such as glaucoma, and anticipates an increase in their use to protect ocular health and enhance chronic disease management.

    This activity is supported by an independent medical education grant from Théa Pharma.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Review the perceptions of preservatives on a global scale and discuss changes observed in patients after implementing preservative-free therapies

  • Accreditation

    Jointly Provided by Evolve Medical Education and The Fundingsland Group.

              

    Accreditation Statement
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC (Evolve) and The Fundingsland Group. Evolve is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation Statement
    Evolve Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Participation Method

    In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

  • Faculty and Disclosures

    Anton Hommer, MD

    Anton Hommer, MD

    Private office for Ophthalmology
    and Optometry
    Vienna, Austria

     

    DISCLOSURE POLICY
    It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

    The following faculty/staff members have the following financial relationships with ineligible companies.

    Anton Hommer, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Nidek. Speaker's Bureau: AbbVie, Interzeag, Santen, and Théa Pharma.

    The Evolve and The Fundingsland Group staff and planners have no financial relationships with ineligible companies.
    Nisha Mukherjee, MD, peer reviewer, has no financial relationships with ineligible companies.

  • Disclaimer

    OFF-LABEL STATEMENT
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group, or Théa Pharma.

    This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Program Chapters

Segment Chapters

Playlist:

Recommended

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
PrevNext